Home » Stocks » DNLI

Denali Therapeutics Inc. (DNLI)

Stock Price: $77.51 USD 1.53 (2.01%)
Updated Jan 20, 2021 4:00 PM EST - Market closed
Market Cap 9.33B
Revenue (ttm) 23.52M
Net Income (ttm) -227.77M
Shares Out 107.49M
EPS (ttm) -2.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $77.51
Previous Close $75.98
Change ($) 1.53
Change (%) 2.01%
Day's Open 76.49
Day's Range 75.50 - 80.43
Day's Volume 533,120
52-Week Range 14.20 - 93.56

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineere...

GlobeNewsWire - 1 week ago

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineere...

The Motley Fool - 4 weeks ago

2020 is almost over. Maybe it's time to cash in -- and cash out?

Other stocks mentioned: BLNK, MDB, AMPE
Zacks Investment Research - 4 weeks ago

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

Other stocks mentioned: CRSP, MCRB, NK, RCKT
InvestorPlace - 1 month ago

It's a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.

Other stocks mentioned: BNTX, CRSP, MRTX, NVAX, SGEN, ZLAB
The Motley Fool - 2 months ago

While most investors are watching the companies working to end the COVID-19 crisis, take a moment to consider three that are continuing the fight against an even more stubborn disease.

Other stocks mentioned: RHHBY, SAVA
Zacks Investment Research - 2 months ago

Denali Therapeutics (DNLI) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineere...

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineere...

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineere...

GlobeNewsWire - 3 months ago

— Webinar scheduled for Thursday, October 15th at 1:00 p.m. Eastern Time —

Zacks Investment Research - 5 months ago

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 8.20% and 57.60%, respectively, for the quarter ended June 2020.

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates enginee...

24/7 Wall Street - 5 months ago

Denali Therapeutics Inc. (NASDAQ: DNLI) announced early on Thursday that it would be progressing its Parkinson’s treatment into late-stage studies, and investors cheered on this move.

Benzinga - 5 months ago

Shares of Denali Therapeutics Inc (NASDAQ: DNLI) are racing toward their 52-week high following a clinical pipeline update concerning the company's Parkinson's disease pipeline.

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates enginee...

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates enginee...

Zacks Investment Research - 5 months ago

Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 7 months ago

SOUTH SAN FRANCISCO, June 09, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to c...

GlobeNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engine...

Zacks Investment Research - 7 months ago

Denali Therapeutics Inc. (DNLI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research - 8 months ago

Denali Therapeutics Inc (DNLI) delivered earnings and revenue surprises of 3.51% and -39.19%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for t...

GlobeNewsWire - 9 months ago

SOUTH SAN FRANCISCO, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engine...

Zacks Investment Research - 10 months ago

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -5.66% and -70.26%, respectively, for the quarter ended December 2019.

Zacks Investment Research - 11 months ago

Denali Therapeutics Inc. (DNLI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research - 11 months ago

Is (DNLI) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 11 months ago

SOUTH SAN FRANCISCO, Calif., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the closing of its upsized underwritten public offering of 9,000,000 sh...

Zacks Investment Research - 11 months ago

Denali Therapeutics Inc. (DNLI) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

GlobeNewsWire - 11 months ago

SOUTH SAN FRANCISCO, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 7,826,087 shares of ...

InvestorPlace - 11 months ago

The only thing more important than what to buy is what not to buy. These biotech stocks are at the top of the avoid list.

Other stocks mentioned: BIIB, BLUE, FGEN, GILD, NKTR, REGN
GlobeNewsWire - 11 months ago

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell shares of its common stock in an unde...

Zacks Investment Research - 1 year ago

Denali Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

The Motley Fool - 1 year ago

Shares jump after the company releases upbeat clinical news.

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Denali (DNLI) stock based on the movements in the options market lately.

The Motley Fool - 1 year ago

No new drugs have been approved for Alzheimer’s disease since 2003. However, new approaches may soon bring options for the 5.7 million Americans suffering from the disease.

Other stocks mentioned: ALEC
Zacks Investment Research - 1 year ago

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 9.43% and 25.24%, respectively, for the quarter ended September 2019.

The Motley Fool - 1 year ago

These companies' collaborations with bigger businesses validates their science -- and paves the way for future revenues and profits.

Other stocks mentioned: RGNX
The Motley Fool - 1 year ago

Here's why shares of these drugmakers have a very slim chance to provide anything but losses.

Other stocks mentioned: GERN
GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for n...

Zacks Investment Research - 1 year ago

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -32.61% and -7.06%, respectively, for the quarter ended June 2019.

Seeking Alpha - 1 year ago

Shares have risen by just 5% since December 2017 IPO.

Zacks Investment Research - 1 year ago

The FDA assigns an orphan drug designation and a rare pediatric disease designation to Denali's (DNLI) pipeline candidate, DNL310, for treating patients with Hunter Syndrome. Shares inch up.

Zacks Investment Research - 1 year ago

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -10.81% and -67.35%, respectively, for the quarter ended March 2019.

Zacks Investment Research - 1 year ago

Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

The Motley Fool - 1 year ago

Find out how shares of these biopharmaceutical companies outperformed for some lucky investors with great timing.

Other stocks mentioned: ACAD, MRNA
Forbes - 1 year ago

Here are four stocks to watch with strong price momentum fueled by earnings.

Other stocks mentioned: GH, VRA, YETI

About DNLI

Denali Therapeutics, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule... [Read more...]

Industry
Biotechnology
IPO Date
Dec 8, 2017
CEO
Ryan Watts
Employees
281
Stock Exchange
NASDAQ
Ticker Symbol
DNLI
Full Company Profile

Financial Performance

In 2019, DNLI's revenue was $26.68 million, a decrease of -79.34% compared to the previous year's $129.16 million. Losses were -$197.61 million, 445.3% more than in 2018.

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for DNLI stock is "Buy." The 12-month stock price forecast is 68.20, which is a decrease of -12.01% from the latest price.

Price Target
$68.20
(-12.01% downside)
Analyst Consensus: Buy